Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076671 | 1.00 | TSHR (0.44) | TSHRMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6412487 | 0.91 | BCL2A1 (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6412482 | 0.91 | BCL2A1 (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6076559 | 0.86 | TSHR (0.45) | TSHRMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL6076555 | 0.86 | TSHR (0.45) | TSHRMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL6416924 | 0.86 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL6416927 | 0.86 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL6414935 | 0.85 | BCL2A1 (0.48) | MEN1KMT2ATDP1BCL2A1POLB | |
| SCHEMBL6414940 | 0.85 | BCL2A1 (0.48) | MEN1KMT2ATDP1BCL2A1POLB | |
| SCHEMBL6077322 | 0.85 | USP30 (0.46) | TSHRMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | TSHR 4830/4885MEN1 4784/4885KMT2A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.